Loading organizations...
§ Private Profile · Menlo Park, CA, USA
RapidAI is a technology company.
RapidAI offers an AI-enabled software platform for medical imaging analysis, specializing in urgent neurovascular and cerebrovascular conditions. Its core product processes CT images, assisting clinicians in rapid, accurate diagnosis and treatment decisions for conditions like stroke and aneurysm. This enterprise platform significantly improves efficiency and precision in critical care workflows, providing deep clinical AI to transform patient assessment and care delivery.
Co-founded around 2012 by Dr. Gregory Albers, a distinguished neurology professor and Stanford Stroke Center co-founder, and Karim Karti, RapidAI originated from a critical insight. Dr. Albers' extensive experience highlighted the necessity for swift, precise imaging analysis in stroke management. This drove the application of artificial intelligence to address the acute, time-sensitive challenges of diagnosing and treating these vascular events.
The platform serves hospitals and clinicians globally, enabling faster, more informed patient care. RapidAI’s vision empowers medical professionals with intelligent tools, enhancing diagnostic accuracy and streamlining treatment pathways. The company dedicates itself to advancing clinical AI, combating life-threatening vascular and neurovascular conditions, and ultimately improving patient outcomes through continuous technological innovation and coordinated care.
RapidAI has raised $100.0M across 2 funding rounds.
RapidAI has raised $100.0M in total across 2 funding rounds.
RapidAI has raised $100.0M in total across 2 funding rounds.
RapidAI's investors include David Flannery, Lennertz & Co..
RapidAI is a clinician-founded technology company specializing in deep clinical AI solutions for healthcare imaging and workflow optimization. It builds the Rapid Enterprise™ Platform, a suite of FDA-cleared AI modules that analyze CT scans and other imaging to provide real-time triage, localization, quantification, and actionable insights for conditions like stroke, pulmonary embolism (PE), aneurysms, and trauma[1][5][8]. Serving over 2,300 hospitals in 100+ countries, RapidAI targets radiologists, neurovascular teams, cardiac/vascular specialists, and multidisciplinary care teams, solving critical problems such as delayed diagnosis, workflow inefficiencies, and limited access to time-sensitive treatments[1][2]. By enabling faster decision-making—backed by 700+ publications, 11 NEJM papers, and 25+ trials—it improves patient outcomes, streamlines operations, and boosts financial viability through better resource allocation and referrals[1][5][6].
The platform's growth momentum is strong: from stroke-focused origins to expansions into cardiac/vascular (e.g., Rapid PE solutions) and edge cloud deployments by 2023, with 20M+ scans processed and adoption across 2,000+ sites by 2021[1][5]. This positions RapidAI as a leader in AI-driven precision medicine, reducing treatment windows (e.g., stroke from 6 to 24 hours) and integrating seamlessly with EHRs and PACS for clinician efficiency[5][6][8].
RapidAI traces its roots to 2008 at Stanford University, where the first fully automated image processing platform for neurology was developed to challenge the conventional 6-hour stroke treatment window[5]. Founded in 2011 and headquartered in Menlo Park, California, the company emerged from clinician innovators who theorized stroke damage variability could extend viable treatments, validated through landmark DAWN and DEFUSE 3 trials[2][5][8]. This led to 2018 guideline changes by the American Heart and Stroke Associations, expanding the window to 24 hours based on Rapid imaging[5].
Early traction came from automating CT perfusion analysis, building on the original RAPID software to expedite postprocessing and team sharing, widely used in places like Ontario[8]. Pivotal moments include 2021 global leadership in 60+ countries, 2022 expansions to cardiovascular/endovascular/trauma, and 2023 launches of edge cloud and non-contrast CT for ischemic stroke—humanizing its mission through patient-centered evolution from brain imaging pioneer to enterprise AI platform[4][5].
RapidAI stands out in clinical AI through clinician-driven development, rigorous validation, and seamless integration, going "beyond the algorithm" for deep disease-state visualization rather than mere anomaly detection[1][5][6].
RapidAI rides the AI-in-healthcare wave, specifically deep clinical AI amid radiologist burnout, imaging overload, and demands for precision medicine in neurovascular/vascular care[6]. Timing is ideal post-RSNA24 showcases and guideline shifts, fueled by market forces like aging populations, rising stroke/PE incidence, and regulatory nods (14 FDA clearances)[1][5][6]. It influences the ecosystem by setting standards for validated AI—driving trial enrollments, guideline evolution, and equitable care access in underserved areas—while enabling high-availability deployments in diverse hospital environments via edge Kubernetes[1][4][5]. As AI moves past hype, RapidAI exemplifies practical integration, fostering collaboration and efficiency in a $100B+ radiology market[6][8].
RapidAI is poised for accelerated expansion, leveraging its platform to penetrate life sciences trials and emerging areas like trauma/non-contrast imaging, with trends in edge AI, multimodal data integration, and regulatory harmonization shaping growth[1][4][5]. Expect deeper EHR/EMR synergies, global scale-up beyond 100 countries, and influence via more NEJM-level validations, potentially redefining care pathways as AI adoption matures. This builds on its stroke revolution, delivering the confident, efficient decisions that transform patient outcomes from the first scan.
RapidAI has raised $100.0M across 2 funding rounds. Most recently, it raised $75.0M Series C in July 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 27, 2023 | $75M Series C | David Flannery | — | Announced |
| Sep 1, 2020 | $25M Series B | Lennertz & CO. | — | Announced |